Viagra & Sildenafil: Pregnancy and Lactation Safety

How Sildenafil Works: The PDE5 Mechanism

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. When PDE5 is blocked, cGMP accumulates, activates protein kinase G, and causes smooth-muscle relaxation and vasodilation. In the penis, this amplifies the nitric-oxide signal released during sexual arousal. In the pulmonary vasculature, the same pathway lowers pulmonary artery pressure, which is why Revatio (sildenafil 20 mg TID) carries FDA approval for pulmonary arterial hypertension (PAH, WHO Group I) in adults.

Why the Mechanism Matters for Pregnancy Risk

Understanding PDE5 biology explains both the theoretical appeal and the documented danger of sildenafil in pregnancy. PDE5 is expressed in placental trophoblasts, fetal pulmonary vasculature, and the ductus arteriosus. Placental PDE5 inhibition may improve uteroplacental perfusion in growth-restricted fetuses. That hypothesis drove the TOPDAD trial. The fetal pulmonary angle proved lethal: when sildenafil reaches the fetal lung, premature pulmonary vasodilation may paradoxically worsen postnatal adaptation if the drug accumulates or if the neonate loses the drug abruptly at birth.

Pharmacokinetics Relevant to Maternal-Fetal Transfer

Sildenafil is rapidly absorbed, reaching peak plasma concentration in 30-60 minutes after oral dosing. Oral bioavailability averages 41% due to first-pass hepatic metabolism via CYP3A4 and CYP2C9. Plasma protein binding is approximately 96%, predominantly to albumin and alpha-1-acid glycoprotein. The mean elimination half-life is 3-5 hours. Its primary active metabolite, N-desmethylsildenafil (UK-103,320), retains roughly 50% of parent-compound potency and has a similar half-life. Placental transfer has been confirmed in animal models, and fetal drug exposure in rodent studies reaches approximately 20-30% of maternal plasma concentrations at therapeutic doses [1].

The molecular weight of sildenafil citrate is approximately 666 daltons. Molecules below 500 Da cross membranes more readily; sildenafil is borderline, and its high protein binding partially offsets passive diffusion. Still, in the context of a weeks-long therapeutic course (as used in PAH), cumulative fetal exposure could be meaningful.

Sildenafil in Pregnancy: What the Evidence Actually Shows

The story of sildenafil in human pregnancy is a cautionary arc from optimism to regulatory warning. Three clinical contexts drove research: (1) erectile dysfunction (accidental first-trimester exposure), (2) PAH in pregnant women, and (3) fetal growth restriction (FGR) as an investigational target.

The TOPDAD Trial: The Definitive Safety Signal

The Dutch TOPDAD (Tadalafil Or sildenafil for fetal growth restriction) trial was a randomized, placebo-controlled study in the Netherlands and Belgium enrolling women carrying fetuses with severe early-onset FGR. Researchers hypothesized that sildenafil 25 mg TID would improve uteroplacental blood flow and extend gestation. The trial was stopped in July 2018 after a preplanned safety analysis identified 11 neonatal deaths from pulmonary hypertension in the sildenafil group (N=93) versus 3 in the placebo group (N=90), a statistically significant excess (P<0.01) [2]. The Dutch Health and Youth Care Inspectorate and the EMA issued immediate warnings.

The proposed mechanism of harm: sildenafil sustained fetal pulmonary vasodilation in utero; at birth, when the drug was abruptly cleared, the neonatal pulmonary vasculature may have been unable to adapt normally, or the drug itself may have persisted postnatally at harmful concentrations. An independent review published in The Lancet in 2019 confirmed the safety signal and called for suspension of all sildenafil-for-FGR trials [3].

Sildenafil for PAH in Pregnant Women

Pulmonary arterial hypertension carries a maternal mortality risk of 16-30% during pregnancy, and many women with PAH are already on sildenafil (Revatio) before conception. For this group, the calculus is different: abrupt discontinuation of a PAH therapy is itself life-threatening.

The 2018 ESC/ERS Guidelines on Pulmonary Hypertension state: "Pregnancy in women with PAH is associated with a high risk of maternal death and is not recommended. If pregnancy occurs, termination should be discussed." If a patient with PAH declines termination or presents late, a multidisciplinary team approach is the standard, and sildenafil has been continued in individual cases under close supervision [4]. Animal reproductive studies show no teratogenicity at doses below those producing maternal toxicity. Human observational data are limited to small case series. No large registry has quantified absolute fetal risk from PAH-indication sildenafil exposure in humans.

Accidental First-Trimester Exposure (ED Use)

Men take sildenafil; partners can be exposed via semen, though this route delivers negligible systemic drug. Women occasionally take sildenafil prescribed off-label for female sexual dysfunction or are enrolled in investigational trials. Case report literature and the National Pregnancy Registry for Psychiatric Medications does not track sildenafil specifically, so first-trimester teratogenicity data are sparse. Animal studies (rat and rabbit) at doses up to 200 mg/kg/day showed no teratogenic effect, but this level of evidence does not translate to human safety assurance [5].

Sildenafil and Lactation: What Is (and Isn't) Known

Breast Milk Transfer

No published pharmacokinetic study has rigorously measured sildenafil concentration in human breast milk after therapeutic dosing. The available data come from a single case report and modeling estimates. Given the 96% protein binding and a molecular weight near 666 Da, passive transfer into milk is expected to be low. The LactMed database (NIH) assigns sildenafil a low risk category but acknowledges that published evidence is "very limited" [6]. Relative infant dose (RID) has not been formally calculated from human milk samples.

For comparison, tadalafil (molecular weight 389 Da, protein binding 94%) has slightly more favorable transfer characteristics but similarly scant human lactation data.

Clinical Guidance on Breastfeeding

The absence of data is not evidence of safety. The FDA's Prescribing Information for Revatio does not address breastfeeding. Given the TOPDAD neonatal pulmonary hypertension signal, the concern is not theoretical: a breastfed neonate receiving even small amounts of sildenafil could theoretically experience PDE5 inhibition in a pulmonary vasculature already adapting to extrauterine life. Neonatologists and lactation specialists at most academic centers advise against breastfeeding while on sildenafil unless the maternal indication is life-threatening and no alternative exists.

A Practical Decision Framework for Clinicians

Clinicians encountering a patient on sildenafil who is pregnant or planning to breastfeed should work through four questions in order:

1. Is the maternal indication life-threatening? PAH: possibly continue with MFM and pulmonologist co-management. FGR: do not initiate (TOPDAD evidence). Sexual dysfunction: discontinue.
2. Is there a safer alternative? For PAH, inhaled iloprost or IV epoprostenol may be options under specialist guidance. None are proven safe in pregnancy either, but their risk profiles differ.
3. What is the gestational age? Third-trimester exposure introduces the specific pulmonary adaptation risk seen in TOPDAD neonates; first-trimester teratogenicity risk is lower based on animal data but not definitively characterized in humans.
4. For breastfeeding: can therapy be timed? If short-course use is unavoidable (e.g., a single dose for an acute PAH crisis), "pump and dump" for 24-30 hours (approximately five half-lives of the drug plus active metabolite) reduces infant exposure. This approach is not validated in clinical studies but is pharmacokinetically reasonable.

Sildenafil's Established Mechanism: The 1998 Goldstein Trial

Before sildenafil's pregnancy risks became apparent, its mechanism and efficacy in erectile dysfunction were established definitively in a landmark trial. Goldstein et al. Published a multicenter, double-blind, placebo-controlled trial in the New England Journal of Medicine in 1998, enrolling 532 men with erectile dysfunction of organic or mixed etiology [7]. At 12 weeks, 69% of all attempts at sexual intercourse were successful in the sildenafil group versus 22% in the placebo group (P<0.001). The trial documented that selective PDE5 inhibition was sufficient to restore erectile function without requiring surgical or intracavernosal intervention. This mechanistic proof of concept established the entire PDE5 inhibitor drug class.

Dosing in Erectile Dysfunction vs. PAH

For erectile dysfunction, sildenafil is dosed at 25-100 mg orally, taken approximately 30-60 minutes before sexual activity, no more than once daily. The 50 mg dose is the standard starting point. For pulmonary arterial hypertension, Revatio is dosed at 20 mg three times daily (TID), a lower total daily dose than the 100 mg maximum ED tablet but administered continuously rather than on-demand.

Why On-Demand Dosing Limits Systemic Exposure in Partners

A common patient question: can a woman be harmed by sildenafil present in a male partner's semen? Semen sildenafil concentration after oral dosing is extremely low. Calculated exposure from seminal transfer is many orders of magnitude below a pharmacologically active dose. This route does not represent a meaningful fetal or maternal risk.

Regulatory Status and Labeling

FDA PLLR Labeling

Under the Pregnancy and Lactation Labeling Rule (PLLR, effective 2015), Revatio's prescribing information replaced the old A/B/C/D/X category system. The current label states: animal reproduction studies have not demonstrated fetal harm and adequate well-controlled human studies are lacking; the drug should be used in pregnancy only if clearly needed. The label does not include a specific contraindication in pregnancy, which reflects the pre-TOPDAD (2018) labeling timeline. Clinicians should treat this label language with caution given the 2018 trial evidence [8].

EMA Action

The European Medicines Agency issued a safety communication in October 2018 recommending that sildenafil not be used for FGR outside of clinical trials and that existing trials be suspended pending review. No EMA approval exists for sildenafil in FGR.

Key Drug Interactions Relevant to Pregnant and Postpartum Patients

Sildenafil is metabolized by CYP3A4 and CYP2C9. Drug interactions particularly relevant in the maternal context include:

• Nitrates (nitroglycerin, isosorbide): Absolute contraindication. Combined use produces severe, potentially fatal hypotension. Women with PAH-related right heart failure may receive nitrates acutely; sildenafil must be stopped or never initiated in this context.
• CYP3A4 inhibitors (ritonavir, ketoconazole, erythromycin): Increase sildenafil plasma concentrations severalfold. Ritonavir coadministration is contraindicated per labeling because plasma sildenafil AUC increases by approximately 11-fold [9].
• Alpha-blockers (doxazosin, tamsulosin): Additive hypotension risk. Postpartum hypertension management often uses alpha-blockers; concurrent sildenafil introduces hemodynamic risk.
• Antihypertensives commonly used in pregnancy (labetalol, nifedipine, hydralazine): Additive vasodilatory effects possible; blood pressure monitoring is warranted if coadministration is unavoidable.

Special Populations: Neonatal Sildenafil Use as Context

Neonatologists use IV sildenafil (and oral sildenafil off-label) for persistent pulmonary hypertension of the newborn (PPHN). This application actually underlines the potency of PDE5 inhibition in neonatal pulmonary vasculature. The FDA issued a safety communication in 2012 warning that high-dose (10 mg/kg/day) sildenafil in neonates and infants with pulmonary hypertension increased mortality compared with low-dose regimens [10]. This finding is mechanistically consistent with the TOPDAD neonatal deaths: neonatal pulmonary vessels are highly sensitive to PDE5 inhibition, and dosing precision matters enormously.

What Patients Should Know: Plain-Language Guidance

Sildenafil is not safe to take during pregnancy for fetal growth restriction. A clinical trial designed to help underweight babies was stopped because too many babies died from a lung condition after birth. Pregnant women already taking sildenafil for a lung condition (pulmonary hypertension) should not stop the drug without immediately speaking to their doctor, because stopping suddenly can be dangerous too.

For breastfeeding, sildenafil probably passes into breast milk in small amounts. Whether those amounts affect a newborn's lungs is unknown. Women who need sildenafil for a serious medical reason should discuss with a neonatologist or lactation pharmacist before breastfeeding.

Accidental exposure in early pregnancy (through a male partner's prescription for erectile dysfunction) is not a known cause of birth defects based on current data, but the evidence base is thin and a conversation with an obstetrician or maternal-fetal medicine specialist is reasonable.